Chardan downgraded Tourmaline Bio (TRML) to Neutral from Buy with a $48 price target after the company agreed to be acquired by Novartis (NVS) for $1.4B in cash, or $48 per share. The transaction is expected to close in Q4. The firm believes the deal validates IL-6 as a “versatile target, particularly for cardiovascular indications.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Hold from Buy at Jefferies
- Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
- Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital
- Hold Rating Maintained Amidst Novartis’s Strategic Acquisition of Tourmaline Bio: Balancing Opportunities and Risks
- Tourmaline Bio downgraded to Neutral from Buy at Guggenheim